Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Device Firms Cheer ICD-10 Debut, While Providers Brace For Chaos

This article was originally published in The Gray Sheet

Executive Summary

The ICD-10 health care coding set has finally launched after much debate and delay. Medical device manufacturers cheer the transition as a means to better capture new technology in the insurance system, but health care providers are bracing for technical headaches and the risk of claims not being paid.

You may also be interested in...



Reimbursement Briefs: AMA Wants ICD-10 Halt; News From CMS, AHRQ And OIG

AMA asks CMS to reconsider ICD-10 implementation. CMS explores specialist payment models. AHRQ quality measures clearinghouse endorses new Medicare hip and knee replacement measures tied to readmissions and complications. More reimbursement news.

Costs Are Central To Arguments For And Against Accelerated ICD-10 Adoption

Device firms and others who support accelerated adoption of a greatly expanded health care billing code system, and payers who warn against moving too fast, each are invoking hot-button economic and health reform issues to make their case

HLB Takes First Expansion Step Via Immunomic Acquisition

South Korea’s HLB has begun a new growth phase by taking over US-based clinical stage biotech firm Immunomic Therapeutics. Through the acquisition, it is poised to add new pipeline assets including a Phase II vaccine therapy for glioblastoma and proprietary lysosomal targeting technology.

Topics

UsernamePublicRestriction

Register

MT034260

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel